CardioFocus (Marlborough, MA) has launched its HeartLight endoscopic ablation system, which features visually guided laser balloon catheter technology for treating atrial fibrillation (AF), in Japan. The commercial launch will be managed in conjunction with its distribution partner JapanLifeline Co., Ltd. (JLL; Tokyo, Japan)—the two companies formed a partnership in 2014.
The launch follows the country-wide reimbursement approval under Japan's National Health Insurance granted in July 2018 and the Japanese Ministry of Health, Labour and Welfare regulatory approval received in July 2017. As a CardioFocus distribution partner, JLL will sell the HeartLight system to hospitals in Japan through its electrophysiology division, which includes more than 250 field personnel across 47 offices.
The HeartLight system delivers controlled and consistent pulmonary vein isolation (PVI) treatment of AF. Its direct visualization, titratable laser energy, and universal balloon design provide an effective and safe treatment option for patients whose heart arrhythmias are insufficiently controlled with medication.
For more information, please visit www.cardiofocus.com.